Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Liabilities and Shareholders Equity: 2016-2024

Historic Liabilities and Shareholders Equity for Rocket Pharmaceuticals (RCKT) over the last 9 years, with Dec 2024 value amounting to $527.7 million.

  • Rocket Pharmaceuticals' Liabilities and Shareholders Equity fell 6.52% to $368.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 billion, marking a year-over-year decrease of 6.20%. This contributed to the annual value of $527.7 million for FY2024, which is 6.82% down from last year.
  • According to the latest figures from FY2024, Rocket Pharmaceuticals' Liabilities and Shareholders Equity is $527.7 million, which was down 6.82% from $566.3 million recorded in FY2023.
  • In the past 5 years, Rocket Pharmaceuticals' Liabilities and Shareholders Equity ranged from a high of $590.8 million in FY2020 and a low of $497.0 million during FY2021.
  • Moreover, its 3-year median value for Liabilities and Shareholders Equity was $551.8 million (2022), whereas its average is $548.6 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first spiked by 58.77% in 2020, then dropped by 15.88% in 2021.
  • Yearly analysis of 5 years shows Rocket Pharmaceuticals' Liabilities and Shareholders Equity stood at $590.8 million in 2020, then fell by 15.88% to $497.0 million in 2021, then grew by 11.02% to $551.8 million in 2022, then grew by 2.63% to $566.3 million in 2023, then decreased by 6.82% to $527.7 million in 2024.